The natural history of treated Parkinson’s disease in an incident, community based cohort

Jonathan R Evans,1 Sarah L Mason,1 Caroline H Williams-Gray,1 Thomas Foltynie,2 Carol Brayne,3 Trevor W Robbins,4 Roger A Barker1

ABSTRACT

Background Our understanding of the natural history of idiopathic Parkinson’s disease (PD) remains limited. In the era of potential disease modifying therapies, there is an urgent need for studies assessing the natural evolution of treated PD from onset so that relevant outcome measures can be identified for clinical trials. No previous studies have charted progression in unscreened patients followed from the point of diagnosis.

Methods A representative cohort of 132 PD patients was followed from diagnosis for up to 7.9 years (mean 5.2 years). Comprehensive clinical and neuropsychological evaluations were performed every 18 months. Disease progression was evaluated using well validated clinical measures (motor progression and development of dyskinesia on the Unified PD Rating Scale and Hoehn—Yahr scale, dementia onset according to DSM-IV criteria). Multi-level linear modelling was used to chart the nature and rate of progression in parkinsonian symptoms and signs over time. The prognostic importance of baseline demographic, clinical and genetic variables was evaluated using survival analysis.

Results Axial (gait and postural) symptoms evolve more rapidly than other motor features of PD and appear to be the best index of disease progression. Conversely, conventional outcome measures are relatively insensitive to change over time. Earlier onset of postural instability (Hoehn—Yahr stage 3) is strongly associated with increased age at disease onset and has a significant impact on quality of life.

Conclusions Dementia risk is associated with increased age, impaired baseline semantic fluency and the MAPT H1/H1 genotype. The efficacy of disease modifying therapies may be more meaningfully assessed in terms of their effects in delaying the major milestones of PD, such as postural instability and dementia, since it is these that have the greatest impact on patients.

INTRODUCTION

Parkinson’s disease (PD) is a progressive neurodegenerative disorder of unknown aetiology for which there is no known cure. While symptomatic treatments can ameliorate the core, motor symptoms, we are increasingly looking to deliver therapies to modify the underlying course of the disease. The effectiveness of symptomatic treatment makes it difficult to study the relationship between pathological progression, which we know to be inexorable, and the clinical evolution of the disease: the natural history of treated PD remains poorly characterised.

Improving our understanding of the progression of PD in the era of effective symptomatic treatment is important for a number of reasons. It will aid in prognostication and will also allow the clinical effects of treatment in individual patients to be evaluated against a meaningful baseline. Most topically, understanding progression in PD enables the identification of relevant outcome measures for clinical trials of putative disease modifying agents.

Surprisingly little has been written about the natural evolution of symptoms and signs in PD. Studies from the pretreatment era were not conducted systematically and have proved largely uninformative, and more recent natural history studies have all tended to have short follow-up periods and involve highly selected patients, such as those in placebo arms of clinical trials,3–5 clinic based evaluations in secondary or tertiary care or, where population based cohorts have been studied, recruited patients of varying disease duration.7–8 There are no previous naturalistic studies in PD using unscreened, representative patients followed from diagnosis, which would most accurately recapitulate the evolution of disease in true to life populations encountered in clinical practice.

There is considerable heterogeneity both in the rate of clinical progression and the risk of disease complications in PD but the relative contributions of clinical, genetic and indeed iatrogenic factors to this heterogeneity remain incompletely understood. Our aim in this study was to track the evolution of disease from diagnosis in a representative PD cohort to investigate which clinical measures of motor progression are most sensitive to change with time, and to identify variables which influence progression. This supersedes earlier work in which we have reported the association between age, genotype at the microtubule associated protein τ gene (MAPT) locus (encoding the τ protein) and baseline cognitive profile in determining the risk of incident dementia,10–12 and we present for the first time our data on motor and non-motor outcomes in an unscreened PD population over an extended follow-up period.

METHODS

Patients Subjects were participants in an epidemiological study of incident parkinsonism conducted over a 2 year period between December 2000 and December 2002, full details of which have been published previously.13 Briefly, subjects with new onset parkinsonism were identified in the community in the county of Cambridgeshire using multiple methods (referrals from primary and secondary care physicians, healthcare records screening) to ensure maximal case ascertainment. The cohort of cases...
assessed was unselected and therefore population representative. Suitable patients were recruited to longitudinal follow-up, undergoing repeat assessments at 18–24 month intervals for up to 7.9 years.

The study was approved by the local ethics committee, and written informed consent was obtained from all patients according to the Declaration of Helsinki.

Assessments and outcome measures
The diagnosis of PD was made according to UK Parkinson’s Disease Society (UKPDS) Brain Bank criteria. These criteria were reapplied at the 3.5 year follow-up to minimise clinical misdiagnosis. Patients were assessed in the ‘on’ state and their medication dose recorded as the levodopa equivalent dose (LED) using an algorithm adapted from Brodsky and colleagues, as we have used previously. Average daily LED for each respondent was estimated by calculating the area under the curve of a graph of LED against time (with any dose changes assumed to take place at the midpoint between assessments) and dividing this by their total follow-up period.

PD motor state was evaluated using two widely used rating scales, the Unified Parkinson’s Disease Rating Scale (UPDRS) and the Hoehn–Yahr Scale (HYS). The UPDRS is a comprehensive 44 item scale on which PD symptoms and signs are rated on a ranked, ordinal scale from 0 (absent) to 4 (severe). The UPDRS has subdivisions, with section 2 (impact of symptoms on activities of daily living) and section 5 (objective assessment of motor signs) often reported separately. Section 3 (hereafter UPDRS-3) has been used frequently as an outcome measure in both clinical trials and naturalistic studies. Section 4 records motor complications, including treatment induced dyskinesia. The UPDRS has undergone extensive clinimetric evaluation and is both consistent and reliable.

Using scores from the UPDRS, patients were classified as tremor dominant, postural instability/gait disorder or intermediate at their initial assessment according to the criteria of Zettsky and colleagues. The algorithm described by Levy et al was used to derive a subscore for symptoms and signs relatively refractory to medication (‘dopa-resistant’ symptoms: encompassing scores for speech, posture, gait, postural stability and rising from sitting). Thus three UPDRS subscores, UPDRS-2 (activities of daily living), UPDRS-3 (motor) and UPDRS ‘dopa-resistant’, were defined for each subject at each assessment. In addition, the UPDRS section 4 was used to document the onset of dyskinesias in each subject.

The HYS is a 5 item scale developed in the pre-levodopa era to capture the key elements of progression in PD. While insensitive, one strength of the HYS is that step increases in stage are sensitive 11 and the Hoehn–Yahr Scale (HYS). The UPDRS is a comprehensive 44 item scale on which PD symptoms and signs are rated on a ranked, ordinal scale from 0 (absent) to 4 (severe). The UPDRS has subdivisions, with section 2 (impact of symptoms on activities of daily living) and section 5 (objective assessment of motor signs) often reported separately. Section 3 (hereafter UPDRS-3) has been used frequently as an outcome measure in both clinical trials and naturalistic studies. Section 4 records motor complications, including treatment induced dyskinesia. The UPDRS has undergone extensive clinimetric evaluation and is both consistent and reliable.

Using scores from the UPDRS, patients were classified as tremor dominant, postural instability/gait disorder or intermediate at their initial assessment according to the criteria of Zettsky and colleagues. The algorithm described by Levy et al was used to derive a subscore for symptoms and signs relatively refractory to medication (‘dopa-resistant’ symptoms: encompassing scores for speech, posture, gait, postural stability and rising from sitting). Thus three UPDRS subscores, UPDRS-2 (activities of daily living), UPDRS-3 (motor) and UPDRS ‘dopa-resistant’, were defined for each subject at each assessment. In addition, the UPDRS section 4 was used to document the onset of dyskinesias in each subject.

The HYS is a 5 item scale developed in the pre-levodopa era to capture the key elements of progression in PD. While insensitive, one strength of the HYS is that step increases in stage are generally irrevocable. In particular, the onset of postural instability that characterises HYS stage 3 (HYS-3) has been reported to herald a more rapid stage of motor progression, and is associated with increased mortality. We used the modified version, which defines half point ratings. Dementia was diagnosed according to DSM-IV criteria in subjects with Mini-Mental State Examination (MMSE) score of ≤24, as has been described previously. Self-reported quality of life (QOL) was assessed with the PDQ-39 questionnaire.

Genotyping
DNA was extracted from peripheral blood samples using a standard phenol/chloroform method. Genotyping for rs9468 (MAPT H1/H2 haplotype) was performed using an allelic discrimination assay run on a 7900HT detection system (Applied Biosystems, Foster City, California, USA).

Statistical analysis
Multi-level linear modelling
Progression in UPDRS subscores was analysed using a mixed effects linear model (MLM). MLM is well suited to the analysis of longitudinal clinical data as it allows the modelling of a situation where repeated measures in the same subject are not independent but correlated. To minimise bias, only subjects assessed on three or more occasions were included in the MLM analysis.

Model parameters were specified to allow random slopes and intercepts. An autoregressive (heterogeneous) covariance structure was employed; this assumes measurements made at adjacent time points correlate most strongly and is standard for a repeated measures design. Estimates of the progression on each UPDRS subscore (dependent variable) were derived as the fixed effect regression coefficient against time (independent variable) using a restricted maximum likelihood method. Subscore gradients were compared using the F test, with Bonferroni adjustment for multiple comparisons; higher gradients were presumed to indicate a superior index of progression. The distributions of slope coefficients and residual error terms were analysed to ensure they conformed to a normal distribution.

As individual UPDRS items can only be scored from 0 to 4, theoretically the scale is insensitive to change beyond this. The proportion of UPDRS items rated ‘4’ was calculated across all assessments to assess for such ceiling effects.

Survival analysis
Time of PD diagnosis was defined as t=0. Survival to the onset of HYS-3, diagnosis of dementia and onset of dyskinesia were modelled using Kaplan–Meier analysis. If a landmark was reached, time of onset was taken to be at the midpoint of the preceding inter-assessment interval.

Cox regression was used to investigate covariates which might influence the disease course in PD. These included age at diagnosis, sex, average medication dose, presenting motor phenotype and MAPT genotype. For the dementia analysis, baseline measures of cognitive function were also included: IQ estimated by the National Adult Reading Test, production of F, A, S words in 1 min each (phonemic fluency), animals named in 90 s (semantic fluency) and constructional ability using the intersecting pentagons from the MMSE, scored 0–2 according to the algorithm of Ala and colleagues. Variables were initially evaluated in a univariate analysis. Multivariate analysis was then performed using covariates with an unadjusted p value ≤0.05. The proportional hazards assumption was tested by graphical inspection of log minus log plots.

The relationship between HYS and QOL (PDQ-39) was assessed using analysis of covariance to adjust for the effects of age and disease duration. Post hoc comparisons were performed using Tukey tests with Bonferroni correction.

Statistical analysis was performed in SPSS V.16.0.

RESULTS
Patients
The flowchart in figure 1 illustrates the case identification process. A total of 132 patients (75 men) consistently met UKPDS Brain Bank criteria for PD and were included in the survival analysis. Mean age at diagnosis was 70.1 (SD 9.8), mean follow-up was 5.2 years (SD 1.6) and average LED was 479 mg/day (SD 292). Mean performance on the MMSE at baseline was 28.9 (0.6). Of these, data from ≥3 assessments was available for 122 patients (70 men) and these cases were also included in the
MLM analysis. The equivalent characteristics for this cohort were: mean age 69.5 (9.8), follow-up 5.5 years (1.4), LED 504.9 mg/day (284.2) and baseline MMSE 29.1 (0.7).

Loss to follow-up
By the fourth round of follow-up, conducted at a mean of 6.6 years from entry, 63/122 (51.6%) eligible patients remained in the study. Of the remainder, 38 had died, 16 had withdrawn consent (usually due to dementia) and five could not be contacted and were not known to have died. The Standardised Mortality Ratio calculated using the most up to date available lifetable estimates for the UK population was 1.72 (1.16 e 2.46).

Mixed effects linear model
Data from 523 assessments in 122 patients were analysed. Only 1.5% of UPDRS-2 items and 1.2% of UPDRS items were rated at ceiling (4/4). As over 80% of these occurred at the latest assessment, ceiling effects are unlikely to have influenced measurement of gradients of change.

Gradients of change for UPDRS subscores are shown in figure 2. Post hoc analysis demonstrated that the gradient for the ‘dopa resistant’ subscore was significantly greater than that of both the UPDRS-3 (F=−8.250, p<0.001) and the UPDRS-2 (F=−5.955, p<0.001). The difference between UPDRS-2 and UPDRS-3 gradients was also significant (F=−5.117, p<0.001). Overall mean progression on the UPDRS-3 was 2.24 points/year; on the UPDRS-2, 1.72 points/year. Residual terms generated by the model conformed to a normal distribution.

Survival analysis
Data from 132 subjects, incorporating 541 assessments and 684 person years of follow-up, was evaluated. Median time to HYS-3 was 3.8 years (range 2.8–4.9) (figure 3A). Less than half of the cohort had developed dementia or dyskinesias by the end of the fifth round of follow-up. The estimated mean time to dementia was 6.2 years (range 5.8–6.3) (figure 3B), and mean time to dyskinesia onset was 6.6 years (range 6.5–7.0) (figure 3C).

The results of Cox regression analysis are shown in table 1. In the multivariate model, age and a postural instability/gait disorder phenotype at presentation were predictors of more rapid progression to HYS-3, and age, MAPT H1/H1 genotype and impaired semantic fluency at baseline were associated with an increased risk of dementia. The level of dopaminergic therapy was the only covariate associated with increased risk of dyskinesia. A supplementary Kaplan-Meier analysis of the relationship between duration of levodopa therapy and time to dyskinesia onset produced a shorter estimate of 4.8 years (4.4–5.3) although it should be noted that the majority of patients receiving levodopa were co-medicated with a dopamine agonist.

A PDQ-39 score was available for 511/541 assessments (94.5%). There was a significant positive association between increasing HYS and higher PDQ-39 (worse QOL; F (7,490) =33.5, p<0.001, figure 4). Post hoc comparisons revealed that PDQ-39 was significantly increased at HYS-3 relative both to HYS-1
DISCUSSION
This is the first study to report on the rate and pattern of progression of disease in unselected PD patients followed from diagnosis. As our cohort was recruited from the community and followed naturalistically, these results represent the course of PD as it is encountered in true to life clinical settings. The length of follow-up and number of repeated evaluations are also strengths of our study, minimising the measurement error in our estimates of progression and safeguarding against clinical misdiagnosis.

Our results indicate that in treated PD the average annual progression in motor symptoms is modest and equivalent to 2.2 points/year on the UPDRS-3. Estimates of progression rates from previous studies are compared in table 2.

Table 1  Cox regression analysis of predictor variables for progression to Hoehn—Yahr stage 3, dementia and for the development of treatment induced dyskinesias

<table>
<thead>
<tr>
<th>Baseline variable</th>
<th>Unadjusted RR (95% CI)</th>
<th>p Value</th>
<th>Adjusted RR (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Progression to HYS-3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>1.069 (1.040 to 1.098)</td>
<td>&lt;0.001</td>
<td>1.051 (1.020 to 1.084)</td>
<td>0.001</td>
</tr>
<tr>
<td>Sex (M vs F)</td>
<td>0.903 (0.575 to 1.419)</td>
<td>0.658</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Motor phenotype at presentation†</td>
<td>0.379 (0.233 to 0.616)</td>
<td>&lt;0.001</td>
<td>0.416 (0.239 to 0.724)</td>
<td>0.002</td>
</tr>
<tr>
<td>TD vs PIGD</td>
<td>1.101 (0.567 to 2.135)</td>
<td>0.777</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>TD vs INT</td>
<td>0.999 (0.979 to 1.019)</td>
<td>0.188</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Average LED</td>
<td>1.178 (0.698 to 1.990)</td>
<td>0.539</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>MAPT H1/H1 haplotype</td>
<td>0.978 (0.698 to 1.375)</td>
<td>0.539</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Progression to dementia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>1.120 (1.068 to 1.175)</td>
<td>&lt;0.001</td>
<td>1.123 (1.056 to 1.194)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Sex (M vs F)</td>
<td>0.985 (0.452 to 1.773)</td>
<td>0.751</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Motor phenotype at presentation†</td>
<td>0.412 (0.193 to 0.880)</td>
<td>0.022</td>
<td>0.609 (0.229 to 1.617)</td>
<td>0.319</td>
</tr>
<tr>
<td>TD vs PIGD</td>
<td>1.130 (0.460 to 2.773)</td>
<td>0.790</td>
<td>0.805 (0.264 to 2.454)</td>
<td>0.703</td>
</tr>
<tr>
<td>TD vs INT</td>
<td>3.992 (1.375 to 11.590)</td>
<td>0.011</td>
<td>4.585 (1.457 to 14.430)</td>
<td>0.008</td>
</tr>
<tr>
<td>Average LED</td>
<td>0.997 (0.977 to 1.016)</td>
<td>0.269</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Verbal IQ*</td>
<td>0.977 (0.968 to 0.986)</td>
<td>&lt;0.001</td>
<td>0.984 (0.943 to 1.025)</td>
<td>0.435</td>
</tr>
<tr>
<td>Semantic fluency (≤19)†</td>
<td>7.886 (2.900 to 20.799)</td>
<td>&lt;0.001</td>
<td>3.686 (1.071 to 12.690)</td>
<td>0.039</td>
</tr>
<tr>
<td>Pentagon copying</td>
<td>0 vs 1</td>
<td>3.279 (1.413 to 7.609)</td>
<td>0.006</td>
<td>1.051 (0.313 to 3.532)</td>
</tr>
<tr>
<td>0 vs 2</td>
<td>13.472 (5.67 to 32.00)</td>
<td>&lt;0.001</td>
<td>2.001 (0.553 to 7.240)</td>
<td>0.291</td>
</tr>
<tr>
<td>Progression to dyskinesia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis</td>
<td>0.981 (0.938 to 1.027)</td>
<td>0.417</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Sex (M vs F)</td>
<td>1.210 (0.489 to 2.991)</td>
<td>0.680</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Motor phenotype at presentation†</td>
<td>0.747 (0.282 to 1.976)</td>
<td>0.556</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>TD vs PIGD</td>
<td>0.918 (0.179 to 4.722)</td>
<td>0.919</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Average LED</td>
<td>1.002 (1.001 to 1.003)</td>
<td>0.019</td>
<td>1.002 (1.001 to 1.003)</td>
<td>0.019</td>
</tr>
<tr>
<td>MAPT H1/H1 haplotype</td>
<td>1.178 (0.698 to 1.990)</td>
<td>0.539</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

For non-categorical covariates, RR represents change in risk per unit change in predictor variable.

*Estimated from National Adult Reading Test score.
†Dichotomised about the median value.
‡Phenotype defined according to algorithm of Zetzky et al.

HYS-3, Hoehn—Yahr stage 3; INT, intermediate; LED, levodopa equivalent dose in mg/day; MAPT, microtubule associated protein τ gene; PD, Parkinson’s disease; PIGD, postural instability gait disorder; TD, tremor dominant.

Figure 3  Kaplan–Meier plots of survival to Hoehn–Yahr stage 3 (HYS-3) (A), onset of dementia (B) and onset of treatment induced dyskinesia (C) in the incident cohort.
studies performed in hospital based cohorts at various times from diagnosis are biased towards capturing patients in better prognostic groups which most likely accounts for the very low progression rates reported in some studies of this type. Conversely, although data from the placebo arms of drug studies indicate high rates of clinical progression early in the disease course, the short follow-up periods employed in these studies seriously challenges the UPDRS as an index of disease evolution. Thus although our figure is closest to that of Schrag et al, we would argue that, given the representative nature of our cohort and the prolonged period of follow-up, our estimate is the most accurate yet produced. Furthermore, we have shown that by defining a subset of predominantly axial symptoms, an index of progression more sensitive than the overall UPDRS-3 score, hitherto the gold-standard, can be created. This is consistent with previous reports of increasing axial symptom burden in advanced PD and would suggest that modified rating scales specifically evaluating these symptoms may have clinimetric utility in PD. This is not something which has been specifically addressed in the recent revision of the UPDRS.

HYS-3 is characterised by the onset of axial impairment and is associated with a step deterioration in QOL. Increased age at disease onset is a significant risk factor for progression to HYS-3, likely due to the synergistic effects of age dependent neuronal loss and parkinsonian neurodegeneration in the aged brain. We recognise that the co-occurrence of other age related comorbidities which may independently affect balance, such as peripheral neuropathy or osteoarthritis, may also have contributed to this association. Although our analysis would suggest that presentation with a tremor dominant phenotype offers relative protection from progression, the relevant factor is probably a lower burden of axial symptoms in these patients rather than the presence of tremor.

A potential criticism of our study is that, as patients were consistently assessed in the ‘on’ state, we have measured variability in treatment response rather than true disease progression. We would argue that by assessing patients in the optimum clinical state, our data represent the best outcomes that can be achieved in practice with conventional treatment. In general, therapies purporting to modify the course of the disease should offer improvements over and above what can be achieved with best symptomatic therapy. Furthermore, there is evidence that levodopa itself has either a disease modifying effect or at least a prolonged symptomatic effect. Thus assessing medicated patients in the ‘off’ state is not the same as assessing never medicated patients: even symptomatic treatments may be altering the natural history of PD. Finally, the study of Clissold et al has previously indicated that, beyond 5 years of disease, ‘on’ and ‘off’ scores deteriorate in parallel.

We used a linear model in our analysis of PD progression but there is evidence that the rate of neurodegeneration in PD may follow an exponential course, declining with time. However, a previous study has shown that the trajectory of disease

### Table 2

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Design</th>
<th>No</th>
<th>Total FU</th>
<th>Age at onset (mean (SD))</th>
<th>PD duration at entry (mean (SD))</th>
<th>UPDRS-3 change pa (% max)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DATATOP (1993)</td>
<td>CT</td>
<td>199</td>
<td>6–21 months</td>
<td>61.9 (9.5)</td>
<td>&lt;5 years</td>
<td>8.9 (8.3%)</td>
</tr>
<tr>
<td>Olsson et al.</td>
<td>CT</td>
<td>40</td>
<td>14 months</td>
<td>64.5 (1.8)</td>
<td>3.2 (0.6)</td>
<td>3.5 (3.2%)</td>
</tr>
<tr>
<td>Parks. Study Group (1996)</td>
<td>CT</td>
<td>66</td>
<td>≤12 months</td>
<td>60.7 (10.9)</td>
<td>1.7 (1.4)</td>
<td>5.5 (5.1%)</td>
</tr>
<tr>
<td>Shults et al. (2002)</td>
<td>CT</td>
<td>16</td>
<td>≤16 months</td>
<td>63.1 (12.1)</td>
<td>&lt;5 years</td>
<td>6.5 (6.0%)</td>
</tr>
<tr>
<td>ELDOPA (2004)</td>
<td>CT</td>
<td>90</td>
<td>42 weeks</td>
<td>64.4 (10.4)</td>
<td>0.4 (0.4)</td>
<td>6.4 (5.9%)</td>
</tr>
<tr>
<td>ADAGIO (2009)</td>
<td>CT</td>
<td>545</td>
<td>38 weeks</td>
<td>61.9 (9.7)</td>
<td>0.4 (0.4)</td>
<td>7.3 (4.1%)</td>
</tr>
<tr>
<td>Louis et al. (1999)</td>
<td>C, P</td>
<td>237</td>
<td>Up to 8 years</td>
<td>72.8 (10.5)</td>
<td>6.8 (6.8)</td>
<td>1.5 (1.4%) ‘on’</td>
</tr>
<tr>
<td>Goetz et al. (2000)</td>
<td>H, P</td>
<td>221</td>
<td>Up to 4 years</td>
<td>56.7 (HYS-2)</td>
<td>1.17 (both groups)</td>
<td>0.1 (0.1%) (HYS-2) ‘on’</td>
</tr>
<tr>
<td>Jankovic et al. (2001)</td>
<td>H, P</td>
<td>297</td>
<td>Up to 17 years</td>
<td>59.3 (HYS-3)</td>
<td>6.5 (NR)</td>
<td>1.4 (1.3%) ‘on’</td>
</tr>
<tr>
<td>Alves et al.</td>
<td>H, P</td>
<td>89</td>
<td>8 years</td>
<td>59.4 (9.7)</td>
<td>8.8 (4.8)</td>
<td>3.3 (3.1%) ‘off’</td>
</tr>
<tr>
<td>Schrag et al. (2007)</td>
<td>H, P</td>
<td>128</td>
<td>12 months</td>
<td>57.6 (12)</td>
<td>9.3 (7.4)</td>
<td>3.3 (3.1%) ‘off’</td>
</tr>
<tr>
<td>Harrison et al. (2009)</td>
<td>H, P</td>
<td>162</td>
<td>2.2 years (mean)</td>
<td>58.2 (11)†</td>
<td>7 (6)</td>
<td>0.3 (0.3%) ‘off’</td>
</tr>
<tr>
<td>Present study</td>
<td>C, I</td>
<td>122</td>
<td>5.5 years (mean)</td>
<td>69.5 (9.8)</td>
<td>From diagnosis</td>
<td>2.24 (2.1%) ‘on’</td>
</tr>
</tbody>
</table>

The top panel displays results from the placebo arms of clinical trials, the lower panel results from longitudinal naturalistic studies.

* Rates of progression are estimated in the ‘off’ state unless otherwise indicated, and on the UPDRS-3 except for total UPDRS score.
† Data reported for a larger, cross sectional cohort of 988 cases within which the longitudinal cohort was nested.
C, community based; CT, clinical trial; FU, follow-up; H, hospital based; HYS-2, -3, Hoehn–Yahr stage 2, stage 3; I, incident; NR, not reported; P, prevalent; PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale.
development measured on clinimetric scales does not differ significantly from linearity. As accurate estimates of progression rely on making repeated measures in the same patients, older patients, or those with more aggressive disease, are less likely to be available for follow-up which may lead to underestimation of the overall rate of progression. We have attempted to overcome this through the concomitant use of survival analysis, the outcome of which is less influenced by censored observations.

The mean time to dementia in our cohort was 6.2 years. This is lower than reported in a number of other series despite our cohort being community based and therefore having a relatively old age at disease onset. Dementia risk is associated with increased disease duration, and this lower figure is likely to reflect the fact that in the present study patients were followed from the point of diagnosis. We have shown that our previously reported association between the τ H1/H1 haplotype and dementia risk is maintained at follow-up of up to 7.9 years using statistically robust survival analysis. In a multivariate analysis, increased age and impaired performance on a task of semantic fluency, principally mediated by the temporal lobes, were associated with an increased risk of dementia, but not motor phenotype nor performance on other cognitive tests at baseline. The H1/H1 τ haplotype results in altered cortical τ transcription patterns and, given the reported interaction between τ and α-synuclein, may promote more rapid evolution of Lewy body pathology. The τ genotype had no influence on progression to HYS-3, probably because while the substrate of dementia in PD is generally believed to be cortical PD pathology, axial PD symptoms instead result from involvement of extranigral brainstem loci which may follow a slightly different pathogenic pathway.

Treatment induced dyskinesias were comparatively uncommon in our cohort and occurred at an estimated mean 6.6 years from diagnosis, in line with previous reports from community based series. Adjusting for disease duration, younger age at PD onset was not an independent risk factor for dyskinesia, and we conclude that it is more probable that increased cumulative exposure to dopaminergic therapy over the course of the illness accounts for the previously described association between age at onset and dyskinesia risk.

Finally, we have reported only preliminary mortality data for this cohort. A more detailed analysis will form the basis of a future study, comprising in addition the results of clinico-pathological analysis of subjects who have consented for post mortem brain donation.

CONCLUSION

Our study suggests that the natural history of treated PD is most accurately characterised by the insidious worsening of axial and postural symptoms, superimposed on which disease complications—‘PD milestones’—occur (figure 5). These milestones, which may include the onset of gait freezing or levodopa induced dyskinesias, as well as the development of dementia and postural instability, are the major determinants of sufferers’ experience of the disease. Hitherto, the design of trials of putative disease modifying agents has focused on the demonstration of sustained symptomatic effects (eg, Olanow et al). Such a strategy may not, however, identify effects which translate into clinically meaningful benefits for patients. In our model, the target of such therapies is to shift the time to the major PD milestones into the future, an effect which can be regarded as true modulation of the natural history of the disease.

In the absence of sensitive disease biomarkers, clinical measures of progression will remain a cornerstone of PD research. The existing strategies for measuring PD progression, namely the UPDRS (and presumably the MDS-UPDRS), may only capture aspects of disease evolution in treated patients. Our analysis of motor progression on both HYS and UPDRS converges on the emergence of axial symptoms—dysfunction in posture, gait and balance—in defining the natural history of treated PD. While improvements in clinimetric measurement of such features would have clear potential in evaluating disease progression, in the longer term there is a pressing unmet need to develop therapies specifically to target these features of the disease, and these will obviously encompass disease modifying therapies.

Acknowledgements The authors wish to thank Dr Stan Lazic for assistance with the statistical analysis.

Funding This work was supported by a National Institute of Health research award to Addenbrooke’s Hospital and the University of Cambridge; the Cure Parkinson’s Trust; and Parkinson’s UK. JRE is supported by the Van Geest Foundation through a Gussy Marlowe Clinician Fellowship, and is in receipt of a Raymond and Beverly Sackler Studentship.

Competing interests None.

Ethics approval This study was conducted with the approval of the Cambridge 2 Local Research Ethics Committee.

Contributors JRE wrote the article, which was reviewed by all the listed authors. All authors contributed to the design of the study. SLM, CHW-G and TF collected the data. JRE performed the statistical analysis. Statistical methods were reviewed by RA Barker.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


Information for patients from JNNP

Walking, posture and balance may signal Parkinson's progression

A new study sheds light on how Parkinson's disease progresses, showing that problems with walking, posture and balance worsen most quickly and provide the best indicators that the disease has advanced.

What do we know already?

Parkinson's disease affects how you move. An early sign for many people is trembling in one hand. Over time, you start doing things more and more slowly as your muscles become stiff. You may take shuffling steps. Or you may freeze in mid-stride (doctors call this gait freezing). You may also lean forwards or backwards and fall over easily (this is called postural instability). Later in the disease, some people also develop dementia.

There is no cure for Parkinson's. Treatments can improve symptoms, but the disease continues to get worse over time.

However, not much is known about how best to monitor the progression of Parkinson's, now that people take medicines to control their symptoms. This is important to explore, as it may influence a patient's treatment and care. It's also important from a research perspective, as scientists attempt to develop treatments to slow the disease (called disease modifying agents). If scientists know which symptoms typically signal a worsening of Parkinson's, this can help them determine whether a treatment is helping to control the disease or not.

In the new study, researchers followed 132 people with Parkinson's disease for an average of 5.2 years after their diagnosis. Each person's symptoms and disease progression were evaluated every 18 to 24 months. The participants' average age at diagnosis was 70.

What does the new study say?

Problems with walking, posture and balance got worse more rapidly than other symptoms. They also provided the best indicators of how quickly the disease was progressing and how soon people would reach 'disease milestones'. These are problems that have a big impact on people's quality of
life, such as gait freezing, postural instability, jerking movements (dyskinesias) caused by treatments, and dementia.

The researchers also found that problems with walking, posture and balance provided a better indication of advancing Parkinson's than the usual scales used to monitor the disease.

**How reliable are the findings?**

A key strength of this study is its frequent and detailed follow-up of participants over several years. This provides an in-depth picture of how people's symptoms worsen and their disease progresses over time. The researchers also took into account several factors that might have influenced people's disease progression, including their sex, age at diagnosis, average medication dose and what symptoms they got early on. This strengthens the findings.

However, it's worth noting that the study included only 132 people. We need larger studies to confirm these results.

**Where does the study come from?**

The study was done by researchers at the University of Cambridge and University College London.

**What does this mean for me?**

You may be interested in these findings if you, or someone close to you, has recently been diagnosed with Parkinson's. Having a sense of which symptoms may be tied to faster progression of the disease might help you and your doctor look to the future.

However, bear in mind that this study was designed mainly to provide benchmarks for scientists to gauge whether new treatments are slowing the normal course of the disease. The researchers didn't specifically explore what their findings might mean for patients and the doctors treating them.


__This summary was prepared by the staff of Best Health, BMJ Group's patient information service. This information does not replace medical advice. If you have a medical problem please see your doctor.__

© BMJ Publishing Group Limited 2011. This article may be distributed without further permission for non-commercial use only.

Created September 2011.